Doctors: Early Detection Is Possible for Pancreatic Cancer
We can help people at risk, but it is much more challenging if most people think that early detection and prevention are impossible.
FINDINGSResearchers from UCLA ’s Jonsson Comprehensive Cancer Center have identified a possible new therapeutic strategy using two types of drug inhibitors at once to treat one of the world’s deadliest cancers. The combination approach uses one drug that inhibits the process — known as lysosome — that allows cancer cells to recycle essential nutrients to survive, and another drug that blocks the pathway used to repair DNA. Researchers found the approach to be promising after testing it on pancreatic cancer cells and mice in the laboratory.BACKGROUNDPancreatic cancer, which is the third leading cause...
A new study from the UC San Diego School of Medicine found that pancreatic cancer patients live longer when they have low levels of enzxyme PHLPP1 and high levels of enzyme PKC.
Condition: Pancreatic Cancer Interventions: Procedure: 3D-printed non-coplanar template; Procedure: 3D-printed coplanar template Sponsors: Ruijin Hospital; Hebei General Hospital; Zhongda Hospital; Anhui Provincial Hospital; The Second Hospital of Shandong University; Sun Yat-sen University; Chinese PLA General Hospital; Huadong Hospital; Tengzhou Central People's Hospital Not yet recruiting
Pancreatic cancer is the third leading cause of death related to cancer in the United States. In contrast to colorectal, breast, and lung cancer, the number of cases are increasing, with pancreatic cancer predicted to become the second most common cause of death due to cancer by 2030.1 The 5-year survival for pancreatic cancer is an abysmal 8.5%.2 One key to improving survival in pancreatic cancer is detecting cancer earlier, with some studies demonstrating survival of almost 60% in patients with stage I cancer.
(University of California - San Diego) UC San Diego School of Medicine research sets the stage for clinicians to potentially one day use levels of a pancreatic cancer patient's PHLPP1 and PKC enzymes as a prognostic, and for researchers to develop new therapeutic drugs that inhibit PHLPP1 and boost PKC as a means to treat the disease.
(University of California - Los Angeles Health Sciences) Researchers from UCLA's Jonsson Comprehensive Cancer Center have identified a possible new therapeutic strategy using two types of drug inhibitors at once to treat one of the world's deadliest cancers.
This study aimed at validating prognostic performance of P4HA2 and PRTN3 in a larger cohort of patients. METHODS: The expression of P4HA2 and PRTN3 was evaluated with tissue microarrays and immunohistochemistry in 140 patients with pancreatic cancer who underwent surgical resection. Kaplan-Meier and Cox proportional hazards regression modeling were used to explore the association of P4HA2 and PRTN3, either separately or combined, with clinicopathological factors and survival. RESULTS: Most tumors were positive for P4HA2 (133/140, 95%), whereas 77 tumors (55%) were positive for PRTN3. Expression levels of P4HA2 and ...
Authors: Balboni B, El Hassouni B, Honeywell RJ, Sarkisjan D, Giovannetti E, Poore J, Heaton C, Peterson C, Benaim E, Lee YB, Kim DJ, Peters GJ Abstract INTRODUCTION: RX-3117 is an oral, small molecule cytidine analog anticancer agent with an improved pharmacological profile relative to gemcitabine and other nucleoside analogs. The agent has excellent activity against various cancer cell lines and xenografts including gemcitabine-resistant variants and it has excellent oral bioavailability; it is not a substrate for the degradation enzyme cytidine deaminase. RX-3117 is being evaluated at a daily oral schedule of 70...
Neoadjuvant chemoradiotherapy, potentially relevant to increase resection rate in pancreatic cancer, is still debated.